SkinMedica, Inc. Files Patent and Trade Secret Action Against Histogen, Inc.

SAN DIEGO--(BUSINESS WIRE)--SkinMedica®, Inc. announced that it has initiated a patent and trade secret action against Histogen, Inc., Histogen Aesthetics, LLC and Dr. Gail Naughton, founder, President and Chief Executive Officer of Histogen and Histogen Aesthetics. Dr. Naughton was a co-founder of Advanced Tissue Sciences or ATS, which initiated bankruptcy proceedings in 2002. SkinMedica acquired several assets from ATS, including intellectual property encompassing its NouriCel® technology. The complaint seeks damages and an injunction against the defendants for the development and manufacture of aesthetic and therapeutic products using SkinMedica’s patented conditioned cell culture media technology.